You are here: Home » PTI Stories » National » News
Business Standard

Lupin launches generic antibiotic inhalation solution in US

Press Trust of India  |  New Delhi 

Drug firm today said it has launched its antibiotic in the US market.

The company has launched the product as it has received an approval from the (USFDA) earlier, said in a filing to BSE.

The company's USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml, it added.

The product is indicated for the management of patients with P aeruginosa, said.

As per IQVIA MAT April 2018 data, USP, 300 mg/5 ml, had annual sales of nearly USD 99 million in the American market, it added.

Shares of Lupin today closed at Rs 869.60 per scrip on BSE, up 1.79 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, June 13 2018. 16:45 IST